0001562180-20-004869.txt : 20200702 0001562180-20-004869.hdr.sgml : 20200702 20200702181453 ACCESSION NUMBER: 0001562180-20-004869 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200702 DATE AS OF CHANGE: 20200702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Paggiarino Dario A. CENTRAL INDEX KEY: 0001574261 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51122 FILM NUMBER: 201011319 MAIL ADDRESS: STREET 1: 4025 SORRENTO VALLEY BLVD. CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: EyePoint Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001314102 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 262774444 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-926-5000 MAIL ADDRESS: STREET 1: 480 PLEASANT STREET STREET 2: SUITE B300 CITY: WATERTOWN STATE: MA ZIP: 02472 FORMER COMPANY: FORMER CONFORMED NAME: pSivida Corp. DATE OF NAME CHANGE: 20080619 FORMER COMPANY: FORMER CONFORMED NAME: pSivida LTD DATE OF NAME CHANGE: 20050111 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-06-30 false 0001314102 EyePoint Pharmaceuticals, Inc. EYPT 0001574261 Paggiarino Dario A. C/O EYEPOINT PHARMACEUTICALS, INC. 480 PLEASANT STREET WATERTOWN MA 02472 false true false false Chief Medical Officer Common Stock 2020-06-30 4 M false 41050.00 0.00 A 101193.00 D Common Stock 2020-06-30 4 F false 12049.00 0.757 D 89144.00 D Restricted Stock Units 0.00 2020-06-30 4 M false 41050.00 0.00 D Common Stock 41050.00 82100.00 D No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units The restricted stock units will vest in three equal installments on the following dates: 6.30.2020, 2.28.2021 and 2.28.2022. /s/ John Mercer, Attorney-in-Fact 2020-07-02